Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.

Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J.

Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10.

PMID:
26355708
2.

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J.

Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24.

3.

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.

Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D.

Leuk Res. 2013 Aug;37(8):900-6. doi: 10.1016/j.leukres.2013.03.019. Epub 2013 Apr 25.

PMID:
23623559
4.

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q).

Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21.

5.

Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.

Giagounidis AA.

Semin Hematol. 2012 Oct;49(4):312-22. doi: 10.1053/j.seminhematol.2012.07.001. Review.

PMID:
23079061
6.

Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.

Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Deuson RR.

Am J Hematol. 2012 May;87(5):558-61. doi: 10.1002/ajh.23163. Epub 2012 Mar 28.

7.

Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.

Giagounidis AA, Kulasekararaj A, Germing U, Radkowski R, Haase S, Petersen P, Göhring G, Büsche G, Aul C, Mufti GJ, Platzbecker U.

Leukemia. 2012 Apr;26(4):855-8. doi: 10.1038/leu.2011.268. Epub 2011 Sep 30. No abstract available.

PMID:
21960245
8.

Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.

Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A.

J Clin Oncol. 2011 Jan 20;29(3):303-9. doi: 10.1200/JCO.2010.31.2686. Epub 2010 Dec 13.

PMID:
21149672
9.

Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).

Chen C, Bowen DT, Giagounidis AA, Schlegelberger B, Haase S, Wright EG.

Leukemia. 2010 Nov;24(11):1875-84. doi: 10.1038/leu.2010.182. Epub 2010 Aug 26.

PMID:
20739954
10.

Myelodysplasia or myelodysplastic syndrome?

Giagounidis AA.

Leuk Res. 2009 Aug;33(8):1019. doi: 10.1016/j.leukres.2009.02.012. Epub 2009 Mar 20. No abstract available.

PMID:
19303635
11.

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Prall WC, Czibere A, Grall F, Spentzos D, Steidl U, Giagounidis AAN, Kuendgen A, Otu H, Rong A, Libermann TA, Germing U, Gattermann N, Haas R, Aivado M.

Int J Hematol. 2009 Mar;89(2):173-187. doi: 10.1007/s12185-008-0242-9. Epub 2009 Jan 20.

PMID:
19152102
12.

Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.

Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U.

Ann Hematol. 2009 Jul;88(7):607-11. doi: 10.1007/s00277-008-0673-7. Epub 2009 Jan 16.

PMID:
19148644
13.

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.

Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF.

J Clin Oncol. 2008 Dec 20;26(36):5943-9. doi: 10.1200/JCO.2007.15.5770. Epub 2008 Nov 17.

14.

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.

Giagounidis AA, Germing U, Haase S, Aul C.

Ther Clin Risk Manag. 2007 Aug;3(4):553-62.

15.

The 5q- syndrome.

Giagounidis AA, Aul C.

Cancer Treat Res. 2008;142:133-48. Review. No abstract available.

PMID:
18283785
16.

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA, Aul C, Trümper L, Krieger O, Stauder R, Müller TH, Wimazal F, Valent P, Fonatsch C, Steidl C.

Blood. 2007 Dec 15;110(13):4385-95. Epub 2007 Aug 28.

PMID:
17726160
17.

Decitabine dosage in myelodysplastic syndromes.

Giagounidis AA.

Blood. 2007 Aug 1;110(3):1082-3; author reply 1083. No abstract available.

PMID:
17644750
18.

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M, Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1307-12. Epub 2007 Jan 12.

19.

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.

Giagounidis AA, Haase S, Heinsch M, Göhring G, Schlegelberger B, Aul C.

Ann Hematol. 2007 Feb;86(2):133-7. Epub 2006 Nov 17.

20.

X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.

Aivado M, Gattermann N, Rong A, Giagounidis AA, Prall WC, Czibere A, Hildebrandt B, Haas R, Bottomley SS.

Blood Cells Mol Dis. 2006 Jul-Aug;37(1):40-5. Epub 2006 Jun 2.

PMID:
16735131
21.

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, Campbell LJ, Wang L, Langford CF, Fidler C, Oscier D, Aul C, Wainscoat JS, Boultwood J.

Blood. 2006 Jul 1;108(1):337-45. Epub 2006 Mar 9. Erratum in: Blood. 2006 Aug 15;108(4):1128.

PMID:
16527891
22.

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.

Giagounidis AA, Germing U, Aul C.

Clin Cancer Res. 2006 Jan 1;12(1):5-10. Review.

23.

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).

Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller T, Haas R, Gattermann N, Aul C.

Leukemia. 2005 Dec;19(12):2223-31.

PMID:
16193087
24.

Breast cancer metastasis to the aortic vessel wall.

Giagounidis AA, Heinsch M, von Barany RU, Erlemannb R, Aul C.

Onkologie. 2005 Jun;28(6-7):369. No abstract available.

PMID:
15973777
25.

The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.

Czibere A, Prall WC, Zerbini LF, Grall F, Craigie EC, Ulrich SD, Giagounidis AA, Haas R, Libermann TA, Aivado M.

Cell Cycle. 2005 Jun;4(6):812-7. Epub 2005 Jun 8.

PMID:
15970671
26.

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.

Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C.

Ann Hematol. 2005 Sep;84(9):569-71. Epub 2005 May 13.

PMID:
15891887
27.

Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling.

Aivado M, Spentzos D, Alterovitz G, Otu HH, Grall F, Giagounidis AA, Wells M, Cho JY, Germing U, Czibere A, Prall WC, Porter C, Ramoni MF, Libermann TA.

Clin Chem Lab Med. 2005;43(2):133-40.

PMID:
15843205
28.

Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion.

Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C.

Acta Haematol. 2005;113(2):146-9.

PMID:
15802895
29.

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.

Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M, Ganser A, Aivado M, Heinsch M, Aul C.

Ann Hematol. 2005 Jun;84(6):389-94. Epub 2005 Mar 23.

PMID:
15785949
30.

The 5q- syndrome.

Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C.

Hematology. 2004 Aug;9(4):271-7.

PMID:
15621734
31.

Early plasmacytoid dendritic cell leukemia/lymphoma coexpressing myeloid antigenes.

Giagounidis AA, Heinsch M, Haase S, Aul C.

Ann Hematol. 2004 Nov;83(11):716-21. Epub 2004 Aug 5.

PMID:
15316755
32.

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C.

Leukemia. 2004 Jan;18(1):113-9.

PMID:
14586479
33.

Fournier's gangrene.

Giagounidis AAN, Heinsch M, Kasperk R, Aul C.

Ann Hematol. 2003 Aug;82(8):531-532. doi: 10.1007/s00277-003-0688-z. Epub 2003 Jun 14. No abstract available.

PMID:
12811517
34.

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.

Giagounidis AA, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C.

Eur J Haematol. 2002 Aug;69(2):95-100.

PMID:
12366712
35.

Testicular infiltration in acute myeloid leukemia with complex karyotype including t(8;21).

Giagounidis AA, Hildebrandt B, Braunstein S, Aivado M, Germing U, Heinsch M, Aul C.

Ann Hematol. 2002 Feb;81(2):115-8. Epub 2001 Dec 8.

PMID:
11907795
36.

Acute basophilic leukemia.

Giagounidis AA, Hildebrandt B, Heinsch M, Germing U, Aivado M, Aul C.

Eur J Haematol. 2001 Aug;67(2):72-6.

PMID:
11722593
37.

Patents for intellectual property.

Schäfer S, Giagounidis AA.

Lancet. 2000 Dec 9;356(9246):2016. No abstract available.

PMID:
11130558
38.

Acute promyelocytic leukemia and pregnancy.

Giagounidis AA, Beckmann MW, Giagounidis AS, Aivado M, Emde T, Germing U, Riehs T, Heyll A, Aul C.

Eur J Haematol. 2000 Apr;64(4):267-71.

PMID:
10776699
39.

Pseudomonas aeruginosa orbital phlegmon in a patient treated for myelodysplastic syndrome with concomitant Sjögren's syndrome.

Giagounidis AA, Giagounidis AS, Germing U, Koch JA, Aul C.

Eur J Med Res. 1999 Jan 26;4(1):27-30.

PMID:
9892572
40.

Adenosine is worth trying in patients with paroxysmal supraventricular tachycardia on chronic theophylline medication.

Giagounidis AA, Schäfer S, Klein RM, Aul C, Strauer BE.

Eur J Med Res. 1998 Aug 18;3(8):380-2.

PMID:
9707519
41.

Terathanasia or teratothanasia?

Giagounidis AA, Giagounidis AY, Giagounidis AS, Giagounidis T.

Lancet. 1997 Dec 6;350(9092):1712. No abstract available.

PMID:
9400549
42.

Pseudomonas aeruginosa blepharoconjunctivitis during cytoreductive chemotherapy in a woman with acute lymphocytic leukemia.

Giagounidis AA, Meckenstock G, Flacke S, Burk M, Wehmeier A, Aul C, Schneider W.

Ann Hematol. 1997 Sep;75(3):121-3.

PMID:
9368482
43.

Pathologic rupture of the spleen in hematologic malignancies: two additional cases.

Giagounidis AA, Burk M, Meckenstock G, Koch AJ, Schneider W.

Ann Hematol. 1996 Dec;73(6):297-302. Review.

PMID:
9003161
44.

Erythrocyte indices as screening tests for the differentiation of microcytic anemias.

Burk M, Arenz J, Giagounidis AA, Schneider W.

Eur J Med Res. 1995 Oct 16;1(1):33-7.

PMID:
9392691

Supplemental Content

Loading ...
Support Center